ArticleRegulatory toxicology and pharmacology : RTP2017
On selecting a minimal set of in vitro assays to reliably determine estrogen agonist activity.
Article in Regulatory toxicology and pharmacology : RTP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 53 citations in OpenAlex.
- The E-Morph Screening Assay: Phenotypic Screening for Estrogenic or Anti-estrogenic Compound Activities.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Machine Learning and Large Language Models for Modeling Complex Toxicity Pathways and Predicting Steroidogenesis.Environmental science & technology · 2025Article
- Screening for Endocrine Bioactivity Potential of Tobacco Product Chemicals Including Flavor Chemicals.Environmental toxicology · 2025Article
- Article
- A novel ERβ high throughput microscopy platform for testing endocrine disrupting chemicals.Heliyon · 2024Article
- Exploring the effects of experimental parameters and data modeling approaches on in vitro transcriptomic point-of-departure estimates.Toxicology · 2024Article
- Chemistry domain of applicability evaluation against existing estrogen receptor high-throughput assay-based activity models.Frontiers in toxicology · 2024Article
- Optimizing androgen receptor prioritization using high-throughput assay-based activity models.Frontiers in toxicology · 2024Article
- A tiered testing strategy based on in vitro phenotypic and transcriptomic data for selecting representative petroleum UVCBs for toxicity evaluation in vivo.Toxicological sciences : an official journal of the Society of Toxicology · 2023Article
- New Approach Methodologies for the Endocrine Activity Toolbox: Environmental Assessment for Fish and Amphibians.Environmental toxicology and chemistry · 2023Review
- Vanillin-Based Indolin-2-one Derivative Bearing a Pyridyl Moiety as a Promising Anti-Breast Cancer Agent via Anti-Estrogenic Activity.ACS omega · 2023Article
- High-throughput AR dimerization assay identifies androgen disrupting chemicals and metabolites.Frontiers in toxicology · 2023Article
- Sensitive image-based chromatin binding assays using inducible ERα to rapidly characterize estrogenic chemicals and mixtures.iScience · 2022Article
- Advances in computational methods along the exposure to toxicological response paradigm.Toxicology and applied pharmacology · 2022Article
- Quality Control for Single Cell Imaging Analytics Using Endocrine Disruptor-Induced Changes in Estrogen Receptor Expression.Environmental health perspectives · 2022Article
- A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor α in an MCF-7 Microarray Compendium.Chemical research in toxicology · 2021Article
- Beyond adverse outcome pathways: making toxicity predictions from event networks, SAR models, data and knowledge.Toxicology research · 2021Article
- Derivation of a Human In Vivo Benchmark Dose for Perfluorooctanoic Acid From ToxCast In Vitro Concentration-Response Data Using a Computational Workflow for Probabilistic Quantitative In Vitro to In Vivo Extrapolation.Frontiers in pharmacology · 2021Article
- Endocrine-Disrupting Chemicals' (EDCs) Effects on Tumour Microenvironment and Cancer Progression: Emerging Contribution of RACK1.International journal of molecular sciences · 2020Review
- Selecting a minimal set of androgen receptor assays for screening chemicals.Regulatory toxicology and pharmacology : RTP · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
The US EPA is charged with screening chemicals for their ability to be endocrine disruptors through interaction with the estrogen, androgen and thyroid axes. The agency is exploring the use of high-throughput in vitro assays to use in the Endocrine Disruptor Screening Program (EDSP), potentially as replacements for lower-throughput in vitro and in vivo tests. The first replacement is an integrated computational and experimental model for estrogen receptor (ER) activity, to be used as an alternative to the EDSP Tier 1 in vitro ER binding and transactivation assays and the in vivo uterotrophic bioassay. The ER agonist model uses a set of 16 in vitro assays that incorporate multiple technologies and cell lines and probe multiple points in the ER pathway. Here, we demonstrate that subsets of assays with as few as 4 assays can predict the activity of all 1811 chemicals tested with accuracy equivalent to that of the full 16-assay model. The prediction accuracy against reference chemicals is higher than that of the full chemical set, partly because the larger set contains many chemicals that can cause a variety of types of assay interference There are multiple accurate assay subsets, allowing flexibility in the construction of a multiplexed assay battery. We also discuss the issue of challenging chemicals, i.e. those that can give false positive results in certain assays, and could hence be more problematic when only a few assays are used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.